相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2004
进行中（未招募）
1
100.0%
暂无批准数据
- The federal government will build a $267-million medical countermeasures laboratory in Winnipeg, slated to open in 2033 next to the National Microbiology Laboratory. - The facility aims to bridge a critical gap in testing early-stage vaccines, therapeutics, and diagnostic tools against pathogens with pandemic potential. - Experts caution that sustained, decades-long funding for human talent and research—not just a new building—will determine whether the lab succeeds. - A $10.2-million design contract was awarded to Winnipeg's Architecture49 Inc., with design completion expected by 2029 and construction beginning in 2030.
- IAVI's rVSVΔG-LASV-GPC vaccine candidate demonstrated acceptable safety profile and elicited robust, long-lasting immune responses in a Phase 1 trial with 114 participants from the U.S. and Liberia. - The single-dose vaccine produced cross-reactive antibodies against multiple Lassa virus lineages circulating in West Africa, with no serious adverse events or hearing loss reported during 12-month follow-up. - Results published in the New England Journal of Medicine support advancement to an ongoing Phase 2a trial in West Africa, making this the most advanced Lassa fever vaccine in clinical development. - The vaccine uses the same rVSV platform as Merck's licensed Ebola vaccine ERVEBO, addressing an urgent medical need for a disease causing 5,000-10,000 deaths annually in West Africa.
